Related Experiment Videos
Second-line treatment for primary central nervous system lymphoma
1Department of Radiochemotherapy, San Raffaele H Scientific Institute, Milan, Italy.
British Journal of Cancer
|February 23, 1999
Summary
Salvage therapy significantly improves outcomes for patients with primary central nervous system lymphoma (PCNSL) who experience treatment failure. Early relapse, however, is associated with a poorer time to death, highlighting the importance of timely intervention.
Area of Science:
- Neuro-oncology
- Hematology
- Clinical Medicine
Background:
- Primary central nervous system lymphoma (PCNSL) has a high failure rate after first-line treatment in immunocompetent patients (35-60%).
- Limited data exists on the efficacy and prognostic factors of salvage therapy for PCNSL.
Purpose of the Study:
- To analyze prognostic factors influencing the time to death (TTD) after treatment failure in PCNSL.
- To evaluate the efficacy of salvage therapy in improving outcomes for PCNSL patients with treatment failure.
Main Methods:
- Retrospective analysis of data from 355 PCNSL cases, focusing on 173 patients with treatment failure.
- Comparison of median TTD based on age at relapse, type of failure (relapse vs. progression), time to relapse, and salvage treatment status.
Main Results:
- Salvage therapy significantly increased median TTD from 2 to 14 months (P<0.00001).
- Late relapse was associated with a longer TTD compared to early relapse (P=0.005).
- Multivariate analysis confirmed salvage therapy and time to relapse as independent prognostic factors.
Conclusions:
- Salvage therapy offers a significant survival benefit for PCNSL patients experiencing treatment failure.
- While salvage therapy improves outcomes, specific optimal treatment schedules require further investigation due to treatment variability.